Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci.

[1]  Yusuke Nakamura,et al.  Mutation analysis in the BRCA2 gene in primary breast cancers , 1996, Nature Genetics.

[2]  M. Stratton,et al.  Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus , 1996, Nature Genetics.

[3]  J. Lear,et al.  Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione S-transferase GSTM1 genotypes, skin type and male gender. , 1996, British Journal of Cancer.

[4]  C. Boland,et al.  Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. , 1995, Journal of the National Cancer Institute.

[5]  J. Lancaster,et al.  p53 polymorphism in ovarian and bladder cancer , 1995, The Lancet.

[6]  H. Iketani,et al.  Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients , 1995, Cancer.

[7]  M. Esteller,et al.  Detection of c‐erbB‐2/neu and fibroblast growth factor‐3/INT‐2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction , 1995, Cancer.

[8]  R. Kreienberg,et al.  p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer , 1995, The Lancet.

[9]  A. Fryer,et al.  Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM1, CYP2D6 and smoking. , 1994, Carcinogenesis.

[10]  K. Kinzler,et al.  Has the breast cancer gene been found? , 1994, Cell.

[11]  K. Buetow,et al.  Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  A. Rannug,et al.  Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. , 1994, Carcinogenesis.

[13]  H. Bolt,et al.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. , 1994, The Biochemical journal.

[14]  E. Bowman,et al.  Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. , 1993, Cancer research.

[15]  V. Lazar,et al.  Simple sequence repeat polymorphism within the p53 gene. , 1993, Oncogene.

[16]  M. Inoue,et al.  Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. , 1993, Cancer research.

[17]  K. Nakachi,et al.  Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. , 1991, Journal of biochemistry.

[18]  D. Nebert.  Role of genetics and drug metabolism in human cancer risk. , 1991, Mutation research.

[19]  J. Yagüe,et al.  AccII polymorphism of the p53 gene. , 1990, Nucleic acids research.

[20]  N. Risch,et al.  Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. , 1989, American journal of human genetics.

[21]  H. Bradlow,et al.  Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. , 1984, The Journal of biological chemistry.

[22]  I. Ramzy,et al.  Adenocarcinoma of the endometrium and abnormal ovarian function in young women. , 1978, American journal of obstetrics and gynecology.

[23]  T. Westfall,et al.  ALTERATIONS IN THE , 1985 .

[24]  Lipsett Mb,et al.  Endocrine responsive cancers of man. , 1981 .